Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

[Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].

Wülfing C, Bögemann M, Goebell PJ, Hammerer P, Machtens S, Pfister D, Schwentner C, Steuber T, von Amsberg G, Schostak M.

Urologe A. 2019 Apr 30. doi: 10.1007/s00120-019-0925-2. [Epub ahead of print] Review. German.

PMID:
31041460
2.

Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.

Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, Sommer J, Zengerling F, Trenti E, Pichler R, Belz H, Zastrow S, Winter A, Melchior S, Hammel J, Kranz J, Bolten M, Krege S, Haben B, Loidl W, Ruf CG, Heinzelbecker J, Heidenreich A, Cremers JF, Oing C, Hermanns T, Fankhauser CD, Gillessen S, Reichegger H, Cathomas R, Pichler M, Hentrich M, Eredics K, Lorch A, Wülfing C, Peine S, Wosniok W, Bokemeyer C, Belge G.

J Clin Oncol. 2019 Jun 1;37(16):1412-1423. doi: 10.1200/JCO.18.01480. Epub 2019 Mar 15.

PMID:
30875280
3.

High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma.

Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stöckle M, Becker F, Ströbel P, Wülfing C, Schrader AJ, Barth P, Staehler M, Stief C, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Höfler H, Haferkamp A, Geppert CI, Stöhr C, Hartmann A; German Network Of Kidney Cancer.

Hum Pathol. 2019 Jan;83:212-223. doi: 10.1016/j.humpath.2018.08.006. Epub 2018 Aug 17.

PMID:
30121370
4.

[Myocardial infarction in a young patient with seminoma during chemotherapy with cisplatinum, etoposide, and bleomycin].

Brinkmann M, Tallone EM, Würschmidt F, Wülfing C, Dieckmann KP.

Aktuelle Urol. 2018 Jul 31. doi: 10.1055/a-0649-4878. [Epub ahead of print] German.

PMID:
30064153
6.

The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1.

Radtke A, Hennig F, Ikogho R, Hammel J, Anheuser P, Wülfing C, Belge G, Dieckmann KP.

Urol Int. 2018;100(4):470-475. doi: 10.1159/000488771. Epub 2018 Apr 26.

7.

Neural architecture in lymphoid organs: Hard-wired antigen presenting cells and neurite networks in antigen entrance areas.

Wülfing C, Schuran FA, Urban J, Oehlmann J, Günther HS.

Immun Inflamm Dis. 2018 Jun;6(2):354-370. doi: 10.1002/iid3.223. Epub 2018 Apr 10.

8.

Image-based spatiotemporal causality inference for protein signaling networks.

Ruan X, Wülfing C, Murphy RF.

Bioinformatics. 2017 Jul 15;33(14):i217-i224. doi: 10.1093/bioinformatics/btx258.

9.

[Image enhancement for Germany's urologists : From strategy workshop to the creation of the "urology brand name"].

Wülfing C.

Urologe A. 2017 Aug;56(8):1005-1007. doi: 10.1007/s00120-017-0450-0. Review. German. No abstract available.

PMID:
28744618
10.

Serum Levels of MicroRNA371a-3p: A Highly Sensitive Tool for Diagnosing and Staging Testicular Germ Cell Tumours: A Clinical Case Series.

Anheuser P, Radtke A, Wülfing C, Kranz J, Belge G, Dieckmann KP.

Urol Int. 2017;99(1):98-103. doi: 10.1159/000477446. Epub 2017 Jun 7.

11.

Systems Imaging of the Immune Synapse.

Ambler R, Ruan X, Murphy RF, Wülfing C.

Methods Mol Biol. 2017;1584:409-421. doi: 10.1007/978-1-4939-6881-7_25.

12.

PKCθ links proximal T cell and Notch signaling through localized regulation of the actin cytoskeleton.

Britton GJ, Ambler R, Clark DJ, Hill EV, Tunbridge HM, McNally KE, Burton BR, Butterweck P, Sabatos-Peyton C, Hampton-O'Neil LA, Verkade P, Wülfing ChC, Wraith DC.

Elife. 2017 Jan 31;6. pii: e20003. doi: 10.7554/eLife.20003.

13.
14.

[Evaluation of the decision aid "Entscheidungshilfe Prostatakrebs" from the patients' view : Results from the first three months].

Groeben C, Ihrig A, Hölscher T, Krones T, Kessler E, Kliesch S, Wülfing C, Koch R, Wirth MP, Huber J.

Urologe A. 2016 Dec;55(12):1586-1594. German.

PMID:
27826660
15.

Prospective assessment of perioperative course in 2648 patients after surgical treatment of benign prostatic obstruction.

Bach T, Wölbling F, Gross AJ, Netsch C, Tauber S, Pottek T, Wülfing C, Brunken C.

World J Urol. 2017 Feb;35(2):285-292. doi: 10.1007/s00345-016-1866-7. Epub 2016 Jun 4.

PMID:
27263019
16.

Computational spatiotemporal analysis identifies WAVE2 and cofilin as joint regulators of costimulation-mediated T cell actin dynamics.

Roybal KT, Buck TE, Ruan X, Cho BH, Clark DJ, Ambler R, Tunbridge HM, Zhang J, Verkade P, Wülfing C, Murphy RF.

Sci Signal. 2016 Apr 19;9(424):rs3. doi: 10.1126/scisignal.aad4149.

17.

[Decision aids for patients are widely accepted by German urologists : A survey among members of the German Society of Urology (DGU) and the Federation of German Urologists (BDU)].

Groeben C, Baunacke M, Borkowetz A, Kliesch S, Wülfing C, Ihrig A, Huber J.

Urologe A. 2016 Jun;55(6):784-91. doi: 10.1007/s00120-016-0054-0. German.

PMID:
26969330
18.

Inhibition of diacylglycerol kinase α restores restimulation-induced cell death and reduces immunopathology in XLP-1.

Ruffo E, Malacarne V, Larsen SE, Das R, Patrussi L, Wülfing C, Biskup C, Kapnick SM, Verbist K, Tedrick P, Schwartzberg PL, Baldari CT, Rubio I, Nichols KE, Snow AL, Baldanzi G, Graziani A.

Sci Transl Med. 2016 Jan 13;8(321):321ra7. doi: 10.1126/scitranslmed.aad1565.

19.

[Non-interventional study for the treatment of neutropenia: Use of pegfilgrastim for chemotherapy-induced neutropenia].

Wülfing C, Rexer H.

Urologe A. 2016 Jan;55(1):76-7. doi: 10.1007/s00120-015-0001-5. German. No abstract available.

PMID:
26666910
20.

Dendritic cells and macrophages neurally hard-wired in the lymph node.

Wülfing C, Günther HS.

Sci Rep. 2015 Nov 19;5:16866. doi: 10.1038/srep16866.

21.

Modest Interference with Actin Dynamics in Primary T Cell Activation by Antigen Presenting Cells Preferentially Affects Lamellal Signaling.

Roybal KT, Mace EM, Clark DJ, Leard AD, Herman A, Verkade P, Orange JS, Wülfing C.

PLoS One. 2015 Aug 3;10(8):e0133231. doi: 10.1371/journal.pone.0133231. eCollection 2015.

22.

Early Signaling in Primary T Cells Activated by Antigen Presenting Cells Is Associated with a Deep and Transient Lamellal Actin Network.

Roybal KT, Mace EM, Mantell JM, Verkade P, Orange JS, Wülfing C.

PLoS One. 2015 Aug 3;10(8):e0133299. doi: 10.1371/journal.pone.0133299. eCollection 2015.

23.

T/B-cell interactions are more transient in response to weak stimuli in SLE-prone mice.

Sinai P, Dozmorov IM, Song R, Schwartzberg PL, Wakeland EK, Wülfing C.

Eur J Immunol. 2014 Dec;44(12):3522-31. doi: 10.1002/eji.201444602. Epub 2014 Nov 12.

24.

[Open and minimally invasive partial nephrectomy. Management of complications].

Wülfing C, Humke U.

Urologe A. 2014 Jul;53(7):960-7. doi: 10.1007/s00120-014-3512-6. German.

PMID:
24865243
25.

New inhibitory signaling by CTLA-4.

Wülfing C, Tunbridge HM, Wraith DC.

Nat Immunol. 2014 May;15(5):408-9. doi: 10.1038/ni.2870. No abstract available.

PMID:
24747703
26.

The actin-driven spatiotemporal organization of T-cell signaling at the system scale.

Roybal KT, Sinai P, Verkade P, Murphy RF, Wülfing C.

Immunol Rev. 2013 Nov;256(1):133-47. doi: 10.1111/imr.12103. Review.

PMID:
24117818
27.

Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).

Krege S, Rexer H, vom Dorp F, de Geeter P, Klotz T, Retz M, Heidenreich A, Kühn M, Kamradt J, Feyerabend S, Wülfing C, Zastrow S, Albers P, Hakenberg O, Roigas J, Fenner M, Heinzer H, Schrader M.

BJU Int. 2014 Mar;113(3):429-36. doi: 10.1111/bju.12437.

28.

The lymphoid lineage-specific actin-uncapping protein Rltpr is essential for costimulation via CD28 and the development of regulatory T cells.

Liang Y, Cucchetti M, Roncagalli R, Yokosuka T, Malzac A, Bertosio E, Imbert J, Nijman IJ, Suchanek M, Saito T, Wülfing C, Malissen B, Malissen M.

Nat Immunol. 2013 Aug;14(8):858-66. doi: 10.1038/ni.2634. Epub 2013 Jun 23.

PMID:
23793062
29.

GRB2-mediated recruitment of THEMIS to LAT is essential for thymocyte development.

Paster W, Brockmeyer C, Fu G, Simister PC, de Wet B, Martinez-Riaño A, Hoerter JA, Feller SM, Wülfing C, Gascoigne NR, Acuto O.

J Immunol. 2013 Apr 1;190(7):3749-56. doi: 10.4049/jimmunol.1203389. Epub 2013 Mar 4.

30.

Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.

Jones R, Vuky J, Elliott T, Mead G, Arranz JA, Chester J, Chowdhury S, Dudek AZ, Müller-Mattheis V, Grimm MO, Gschwend JE, Wülfing C, Albers P, Li J, Osmukhina A, Skolnik J, Hudes G.

Invest New Drugs. 2013 Aug;31(4):1001-7. doi: 10.1007/s10637-013-9926-y. Epub 2013 Jan 18.

PMID:
23329066
31.

New TACTICS for finding Numb.

Roybal KT, Wülfing C.

Immunol Cell Biol. 2013 Jan;91(1):1-2. doi: 10.1038/icb.2012.63. Epub 2012 Nov 27. Review. No abstract available.

PMID:
23183270
32.

Mechanism and function of Vav1 localisation in TCR signalling.

Ksionda O, Saveliev A, Köchl R, Rapley J, Faroudi M, Smith-Garvin JE, Wülfing C, Rittinger K, Carter T, Tybulewicz VL.

J Cell Sci. 2012 Nov 15;125(Pt 22):5302-14. doi: 10.1242/jcs.105148. Epub 2012 Sep 6.

33.

[Secondary malignancies in urinary diversions].

Kälble T, Hofmann I, Thüroff JW, Stein R, Hautmann R, Riedmiller H, Vergho D, Hertle L, Wülfing C, Truß M, Roth S, von Rundstedt FC, Albers P, Gschwend J, Herkommer K, Humke U, Spahn M, Bader P, Steffens J, Harzmann R, Stief CG, Karl A, Müller SC, Waldner M, Noldus J, Kleinschmidt K, Alken P, Kopper B, Fisch M, Lampel A, Stenzel A, Fichtner J, Flath B, Rübben H, Juenemann KP, Hautmann S, Knipper A, Leusmann D, Strohmaier W, Thon WF, Miller S, Weingärtner K, Schilling A, Piechota H, Becht JE, Schwaibold H, Bub P, Conrad S, Wenderoth U, Merkle W, Rösch W, Otto T, Ulshöfer B, Westenfelder M.

Urologe A. 2012 Apr;51(4):500, 502-6. doi: 10.1007/s00120-012-2815-8. German.

PMID:
22476801
34.

External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder.

Nuhn P, May M, Fritsche HM, Buchner A, Brookman-May S, Bolenz C, Moritz R, Herrmann E, Burger M, Höfner T, Ellinger J, Tilki D, Roigas J, Zacharias M, Trojan L, Wülfing C, May F, Melchior S, Haferkamp A, Gilfrich C, Hohenfellner M, Wieland WF, Müller SC, Stief CG, Bastian PJ.

Eur J Surg Oncol. 2012 Jul;38(7):637-42. doi: 10.1016/j.ejso.2012.02.187. Epub 2012 Mar 27.

PMID:
22459902
35.

[Practical information on the use of port systems].

Göckschu J, Linbecker M, Wülfing C.

Aktuelle Urol. 2012 Mar;43(2):102-3. doi: 10.1055/s-0031-1284001. Epub 2012 Mar 27. Review. German.

PMID:
22454261
36.

Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.

Schulte A, Günther HS, Martens T, Zapf S, Riethdorf S, Wülfing C, Stoupiec M, Westphal M, Lamszus K.

Clin Cancer Res. 2012 Apr 1;18(7):1901-13. doi: 10.1158/1078-0432.CCR-11-3084. Epub 2012 Feb 7.

37.

Phosphatidylinositol (4,5) bisphosphate controls T cell activation by regulating T cell rigidity and organization.

Sun Y, Dandekar RD, Mao YS, Yin HL, Wülfing C.

PLoS One. 2011;6(11):e27227. doi: 10.1371/journal.pone.0027227. Epub 2011 Nov 11.

38.

Itk controls the spatiotemporal organization of T cell activation.

Singleton KL, Gosh M, Dandekar RD, Au-Yeung BB, Ksionda O, Tybulewicz VL, Altman A, Fowell DJ, Wülfing C.

Sci Signal. 2011 Oct 4;4(193):ra66. doi: 10.1126/scisignal.2001821.

39.

Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder.

May M, Bastian PJ, Burger M, Bolenz C, Trojan L, Herrmann E, Wülfing C, Müller SC, Ellinger J, Buchner A, Stief CG, Tilki D, Otto W, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Wieland WF, Fritsche HM.

BJU Int. 2011 Oct;108(8 Pt 2):E278-83. doi: 10.1111/j.1464-410X.2011.10189.x. Epub 2011 Jun 23.

40.

The CD3 zeta subunit contains a phosphoinositide-binding motif that is required for the stable accumulation of TCR-CD3 complex at the immunological synapse.

DeFord-Watts LM, Dougall DS, Belkaya S, Johnson BA, Eitson JL, Roybal KT, Barylko B, Albanesi JP, Wülfing C, van Oers NS.

J Immunol. 2011 Jun 15;186(12):6839-47. doi: 10.4049/jimmunol.1002721. Epub 2011 May 4.

41.

Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder.

May M, Bastian PJ, Brookman-May S, Burger M, Bolenz C, Trojan L, Michel MS, Herrmann E, Wülfing C, Tiemann A, Müller SC, Ellinger J, Buchner A, Stief CG, Tilki D, Wieland WF, Gilfrich C, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Gunia S, Fritsche HM.

Scand J Urol Nephrol. 2011 Sep;45(4):251-7. doi: 10.3109/00365599.2011.562235. Epub 2011 Mar 10.

PMID:
21388337
42.

[Validation of pre-cystectomy nomograms for the prediction of locally advanced urothelial bladder cancer in a multicentre study: are we able to adequately predict locally advanced tumour stages before surgery?].

May M, Burger M, Brookman-May S, Otto W, Peter J, Rud O, Fritsche HM, Bolenz C, Trojan L, Herrmann E, Michel MS, Wülfing C, Moritz R, Tiemann A, Müller SC, Ellinger J, Buchner A, Stief CG, Tilki D, Wieland WF, Gilfrich C, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Bretschneider-Ehrenberg P, Müller O, Zacharias M, Gunia S, Bastian PJ.

Urologe A. 2011 Jun;50(6):706-13. doi: 10.1007/s00120-011-2506-x. German.

PMID:
21340594
43.

[Influence of older age on survival after radical cystectomy due to urothelial carcinoma of the bladder: survival analysis of a German multi-centre study after curative treatment of urothelial carcinoma of the bladder].

May M, Fritsche HM, Gilfrich C, Brookman-May S, Burger M, Otto W, Bolenz C, Trojan L, Herrmann E, Michel MS, Wülfing C, Tiemann A, Müller SC, Ellinger J, Buchner A, Stief CG, Tilki D, Wieland WF, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Müller O, Bretschneider-Ehrenberg P, Zacharias M, Gunia S, Bastian PJ.

Urologe A. 2011 Jul;50(7):821-9. doi: 10.1007/s00120-011-2507-9. German.

PMID:
21340593
44.

Tentative and transient natural killer cell polarization balances the requirements for discriminatory recognition and cytolytic efficacy.

Sinai P, Roybal KT, Wülfing C.

Commun Integr Biol. 2010 Nov;3(6):545-8. doi: 10.4161/cib.3.6.12843. Epub 2010 Nov 1.

45.

Combined immunochemotherapy in selected patients with metastatic renal cell carcinoma: HLA class II genotype can help to predict response to therapy.

Bierer S, Hoffmeister I, Gerss J, Herrmann E, Wülfing C, Sibrowski W, Hertle L, Kelsch R.

J Immunother. 2011 Mar;34(2):196-201. doi: 10.1097/CJI.0b013e3182027748.

PMID:
21304400
46.

Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy.

May M, Herrmann E, Bolenz C, Tiemann A, Brookman-May S, Fritsche HM, Burger M, Buchner A, Gratzke C, Wülfing C, Trojan L, Ellinger J, Tilki D, Gilfrich C, Höfner T, Roigas J, Zacharias M, Gunia S, Wieland WF, Hohenfellner M, Michel MS, Haferkamp A, Müller SC, Stief CG, Bastian PJ.

Eur Urol. 2011 May;59(5):712-8. doi: 10.1016/j.eururo.2011.01.030. Epub 2011 Jan 28.

PMID:
21296488
47.

Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy.

May M, Herrmann E, Bolenz C, Brookman-May S, Tiemann A, Moritz R, Fritsche HM, Burger M, Trojan L, Michel MS, Wülfing C, Müller SC, Ellinger J, Buchner A, Stief CG, Tilki D, Wieland WF, Gilfrich C, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Bastian PJ.

Ann Surg Oncol. 2011 Jul;18(7):2018-25. doi: 10.1245/s10434-010-1538-6. Epub 2011 Jan 19.

PMID:
21246405
48.

[Patients with bladder cancer in clinical stage T2 : survival benefit of downstaging in comparison to patients with confirmed muscle invasion in cystectomy specimens].

May M, Fritsche HM, Brookman-May S, Burger M, Bolenz C, Trojan L, Herrmann E, Michel MS, Wülfing C, Tiemann A, Müller SC, Ellinger J, Buchner A, Stief CG, Tilki D, Wieland WF, Gilfrich C, Höfner T, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Gunia S, Bastian PJ.

Urologe A. 2010 Dec;49(12):1508-15. doi: 10.1007/s00120-010-2424-3. German.

PMID:
20922515
49.

Inhibiting the inhibitor of the inhibitor: blocking PKC-theta to enhance regulatory T cell function.

Roybal KT, Wülfing C.

Sci Signal. 2010 Jul 27;3(132):pe24. doi: 10.1126/scisignal.3132pe24.

PMID:
20664063
50.

Negative predictive value of systematic ultrasound-guided prostate biopsy: which tumours do we miss?

Köpke T, Oberpenning F, Bettendorf O, Eltze E, Herrmann E, Hertle L, Weining C, Wulfing C, Semjonow A.

Anticancer Res. 2010 May;30(5):1823-7.

PMID:
20592386

Supplemental Content

Loading ...
Support Center